RxDoctor Payments DataLook up a doctor →

William Lyles, MD

Gastroenterology · Maryville, TNNPI 1750364782

Payments from drug & device makers

$151,200in general payments, 2019–2025

Across 1,018 payments — averaging $148.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$98K
  • Pfizer$29K
  • Phathom Pharmaceuticals, Inc.$14K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $6K from 33 others

What the payments were for

  • Consulting fees$4,8003%
  • Speaking & faculty fees$117,22878%
  • Travel & lodging$9,9807%
  • Food & beverage$19,08613%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$151,200 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$93,265
Medicare patients
336
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$299,266
ZenpepLipase/Protease/Amylase12$84,589
Humira(Cf) PenAdalimumab12$78,752
XifaxanRifaximin17$60,559
LinzessLinaclotide28$26,233
Dexlansoprazole DrDexlansoprazole33$12,856
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates147$9,608
SutabSod Sulf/Pot Chloride/Mag Sulf44$7,150
Mesalamine24$6,101
Mesalamine ErMesalamine29$4,323
Omeprazole325$4,161
Colesevelam Hcl36$4,127
ClenpiqSod Picosulf/Mag Ox/Citric Ac18$3,048
Ondansetron OdtOndansetron110$1,772
Budesonide EcBudesonide11$1,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,296$299,26611 claims
Aimmune Therapeutics, Inc.Zenpep$319$84,58912 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,189$60,55917 claims
AbbVieLinzess$98,313$26,23328 claims
Braintree Laboratories, Inc.Sutab$73$7,15044 claims
Ferring Pharmaceuticals Inc.Clenpiq$134$3,04818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →